EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice

Melanie Modder iD, Wietse In Het Panhuis iD, Mohan Li, Salwa Afkir, Alexandra L Dorn, Amanda C M Pronk, Trea C M Streefland, Reshma A Lalai, Stefan Pierrou iD, Stefan K Nilsson iD, Gunilla Olivecrona iD, Sander Kooijman iD und 2 weitere

Cardiovascular Research · 31.12.2024 · 120 (17) · 2179-2190

DOI: 10.1093/cvr/cvae195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 11.09.2024. Verfasst von Melanie Modder und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 4, Atherosclerosis, Liver, Oligonucleotides, Antisense. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Heart Foundation, Netherlands Cardiovascular Research, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Angiopoietin-like 3 (ANGPTL3) and 4 (ANGPTL4) inhibit lipoprotein lipase to regulate tissue fatty acid (FA) uptake from triglyceride (TG)-rich lipoproteins such as very low density lipoproteins (VLDL). While pharmacological inhibition of ANGPTL3 is being evaluated as a lipid-lowering strategy, systemic ANGPTL4 inhibition is not pursued due to adverse effects. This study aims to compare the therapeutic potential of liver-specific Angptl3 and Angptl4 silencing to attenuate hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice, a well-established humanized model for lipoprotein metabolism. Methods and results Mice were subcutaneously injected twice per week with saline or liver-targeted antisense oligonucleotides against Angptl3, Angptl4, both, or a scrambled oligonucleotide. Plasma lipid levels, VLDL clearance, and hepatic VLDL production were determined, and atherosclerosis development was assessed. For toxicological evaluation, cynomolgus monkeys were treated with three dosages of liver-targeted ANGPTL4-silencing oligonucleotides. Liver-targeted Angptl4 silencing reduced plasma TGs (−48%) and total cholesterol (−56%), explained by higher VLDL-derived FA uptake by brown adipose tissue and lower VLDL production by the liver. Accordingly, Angptl4 silencing reduced atherosclerotic lesion size (−86%) and improved lesion stability. Hepatic Angptl3 silencing similarly attenuated hyperlipidemia and atherosclerosis development. While Angptl3 and Angptl4 silencing lowered plasma TGs in the refed and fasted state, respectively, combined Angptl3/4 silencing lowered plasma TGs independent of the nutritional state. In cynomolgus monkeys, anti-ANGPTL4 ASO treatment was well tolerated without adverse effects.

Conclusion

Liver-targeted Angptl4 silencing potently attenuates hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice, and liver-targeted ANGPTL4 silencing is well tolerated in non-human primates. These data warrant further clinical development of liver-targeted ANGPTL4 silencing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiopoietin-Like Protein 4AtherosclerosisLiverOligonucleotides, AntisenseAngiopoietin-Like Protein 3Apolipoprotein E3HyperlipidemiasDisease Models, AnimalCholesterol Ester Transfer ProteinsAnimalsMacaca fascicularisMaleLipoproteins, VLDLAngiopoietin-like ProteinsHumansMice, TransgenicAngiopoietinsMicePlaque, AtheroscleroticTriglycerides

Stichwörter der Autor:innen

Angptl3Angptl4Antisense oligonucleotidesAtherosclerosisHyperlipidaemia

Substanzen

Angiopoietin-Like Protein 4Oligonucleotides, AntisenseAngiopoietin-Like Protein 3Apolipoprotein E3Angptl4 protein, mouseCholesterol Ester Transfer ProteinsAngptl3 protein, mouseapolipoprotein E3 (Leidein)Lipoproteins, VLDLAngiopoietin-like Proteins

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
  • Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
  • Lipigon Pharmaceuticals AB, Tvistevägen 48C, 907 36 Umeå, Sweden.
  • Department of Medical Biosciences, Umeå University, Umeå, Sweden.

ORCID-Profile: Melanie Modder, Wietse In Het Panhuis, Stefan Pierrou, Stefan K Nilsson, Gunilla Olivecrona, Sander Kooijman, Patrick C N Rensen, Milena Schönke

Förderung

  • Dutch Heart Foundation
  • Netherlands Cardiovascular Research
  • Novo Nordisk Foundation

Zitieren

APA

Modder, M., Het Panhuis, W. I., Li, M., Afkir, S., Dorn, A. L., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., Pierrou, S., Nilsson, S. K., Olivecrona, G., Kooijman, S., Rensen, P. C. N., & Schönke, M. (2024). Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Cardiovascular Research, 120(17), 2179-2190. https://doi.org/10.1093/cvr/cvae195

Vancouver

Modder M, Het Panhuis WI, Li M, Afkir S, Dorn AL, Pronk ACM, et al. Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Cardiovascular Research. 2024;120(17):2179-2190. doi:10.1093/cvr/cvae195

BibTeX
@article{Modder2024,
  author = {Modder, Melanie and Het Panhuis, Wietse In and Li, Mohan and Afkir, Salwa and Dorn, Alexandra L and Pronk, Amanda C M and Streefland, Trea C M and Lalai, Reshma A and Pierrou, Stefan and Nilsson, Stefan K and Olivecrona, Gunilla and Kooijman, Sander and Rensen, Patrick C N and Schönke, Milena},
  title = {Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice},
  journal = {Cardiovascular Research},
  year = {2024},
  volume = {120},
  number = {17},
  pages = {2179--2190},
  doi = {10.1093/cvr/cvae195}
}
Kostenlos starten →